Translational Medicine Research Center, Guizhou Medical University, Guiyang, Guizhou, China.
Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2398561. doi: 10.1080/14756366.2024.2398561. Epub 2024 Sep 2.
Obesity is acknowledged as a significant risk factor for various metabolic diseases, and the inhibition of human pancreatic lipase (hPL) can impede lipid digestion and absorption, thereby offering potential benefits for obesity treatment. Anthraquinones is a kind of natural and synthetic compounds with wide application. In this study, the inhibitory effects of 31 anthraquinones on hPL were evaluated. The data shows that AQ7, AQ26, and AQ27 demonstrated significant inhibitory activity against hPL, and exhibited selectivity towards other known serine hydrolases. Then the structure-activity relationship between anthraquinones and hPL was further analysed. AQ7 was found to be a mixed inhibition of hPL through inhibition kinetics, while AQ26 and AQ27 were effective non-competitive inhibition of hPL. Molecular docking data revealed that AQ7, AQ26, and AQ27 all could associate with the site of hPL. Developing hPL inhibitors for obesity prevention and treatment could be simplified with this novel and promising lead compound.
肥胖被认为是多种代谢性疾病的重要危险因素,而抑制人胰腺脂肪酶(hPL)可以阻止脂肪的消化和吸收,从而为肥胖治疗带来潜在的益处。蒽醌类化合物是一种具有广泛应用的天然和合成化合物。在本研究中,评估了 31 种蒽醌类化合物对 hPL 的抑制作用。结果表明,AQ7、AQ26 和 AQ27 对 hPL 表现出显著的抑制活性,并且对其他已知的丝氨酸水解酶具有选择性。然后进一步分析了蒽醌类化合物与 hPL 之间的构效关系。通过抑制动力学发现,AQ7 是 hPL 的混合抑制物,而 AQ26 和 AQ27 则是有效的非竞争性抑制物。分子对接数据表明,AQ7、AQ26 和 AQ27 均可与 hPL 的结合位点结合。开发用于预防和治疗肥胖症的 hPL 抑制剂可以简化为这个新颖而有前景的先导化合物。